Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Renal tumor size is an independent prognostic factor for overall survival in von Hippel-Lindau disease.

Kwon T, Jeong IG, Pak S, You D, Song C, Hong JH, Ahn H, Kim CS.

J Cancer Res Clin Oncol. 2014 Jul;140(7):1171-7. doi: 10.1007/s00432-014-1654-y. Epub 2014 Mar 27.

PMID:
24671227
2.

Clinical characteristics of renal cell carcinoma in Korean patients with von Hippel-Lindau disease compared to sporadic bilateral or multifocal renal cell carcinoma.

Kim WT, Ham WS, Ju HJ, Lee JS, Lee JS, Choi YD.

J Korean Med Sci. 2009 Dec;24(6):1145-9. doi: 10.3346/jkms.2009.24.6.1145. Epub 2009 Nov 9.

3.

Survival and causes of death in patients with von Hippel-Lindau disease.

Binderup ML, Jensen AM, Budtz-Jørgensen E, Bisgaard ML.

J Med Genet. 2017 Jan;54(1):11-18. doi: 10.1136/jmedgenet-2016-104058. Epub 2016 Aug 18.

PMID:
27539272
4.

A case of von Hippel-Lindau disease with bilateral pheochromocytoma, renal cell carcinoma, pelvic tumor, spinal hemangioblastoma and primary hyperparathyroidism.

Arao T, Okada Y, Tanikawa T, Inatomi H, Shuin T, Fujihira T, Yamashita H, Tanaka Y.

Endocr J. 2002 Apr;49(2):181-8.

5.

First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.

Roma A, Maruzzo M, Basso U, Brunello A, Zamarchi R, Bezzon E, Pomerri F, Zovato S, Opocher G, Zagonel V.

Fam Cancer. 2015 Jun;14(2):309-16. doi: 10.1007/s10689-014-9771-y.

PMID:
25391617
6.

Nephron sparing surgery in von Hippel-Lindau associated renal cell carcinoma; clinicopathological long-term follow-up.

Jilg CA, Neumann HP, Gläsker S, Schäfer O, Leiber C, Ardelt PU, Schwardt M, Schultze-Seemann W.

Fam Cancer. 2012 Sep;11(3):387-94. doi: 10.1007/s10689-012-9525-7.

PMID:
22426863
7.

[Sarcomatoid renal cell carcinoma with von Hippel-Lindau disease: a case report].

Minagawa T, Nishizawa S, Kamigaito M, Nakayama T, Okaneya T.

Nihon Hinyokika Gakkai Zasshi. 2007 Jul;98(5):723-6. Japanese.

8.

[A case of renal cell carcinoma associated with von Hippel-Lindau disease and the necessity for family genetic diagnosis].

Nanri M, Uda M, Iguchi Y, Gouya N, Toma H, Kihara T.

Hinyokika Kiyo. 1999 Nov;45(11):755-8. Japanese.

9.

Growth kinetics in von Hippel-Lindau-associated renal cell carcinoma.

Jilg CA, Neumann HP, Gläsker S, Schäfer O, Ardelt PU, Schwardt M, Schultze-Seemann W.

Urol Int. 2012;88(1):71-8. doi: 10.1159/000333348. Epub 2011 Dec 9.

10.

Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients.

Mans DA, Vermaat JS, Weijts BG, van Rooijen E, van Reeuwijk J, Boldt K, Daenen LG, van der Groep P, Rowland BD, Jans JJ, Roepman R, Voest EE, van Diest PJ, Verhaar MC, de Bruin A, Giles RH.

J Pathol. 2013 Sep;231(1):117-29. doi: 10.1002/path.4219.

PMID:
23744542
11.

Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma.

Neumann HP, Bender BU, Berger DP, Laubenberger J, Schultze-Seemann W, Wetterauer U, Ferstl FJ, Herbst EW, Schwarzkopf G, Hes FJ, Lips CJ, Lamiell JM, Masek O, Riegler P, Mueller B, Glavac D, Brauch H.

J Urol. 1998 Oct;160(4):1248-54.

PMID:
9751329
12.

Management of renal cell carcinoma in von Hippel-Lindau disease.

Hes FJ, Slootweg PJ, van Vroonhoven TJ, Hené RJ, Feldberg MA, Zewald RA, Ploos van Amstel JK, Höppener JW, Pearson PL, Lips CJ.

Eur J Clin Invest. 1999 Jan;29(1):68-75.

PMID:
10092992
13.

Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.

Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K, Simko J, Small EJ, Waldman FM.

BJU Int. 2006 Oct;98(4):756-62. Epub 2006 Jul 7.

14.

[Clinicopathologic study of von Hippel-Lindau syndrome-related and sporadic hemangioblastomas of central nervous system].

Zhou J, Li NY, Zhou XJ, Zhou HB, Wu B, Jiang SJ, Ma HH, Zhang RS.

Zhonghua Bing Li Xue Za Zhi. 2010 Mar;39(3):145-50. Chinese.

PMID:
20450758
15.

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.

Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R.

J Urol. 2008 Sep;180(3):860-5; discussion 865-6. doi: 10.1016/j.juro.2008.05.015. Epub 2008 Jul 17.

PMID:
18635227
16.

Active surveillance of renal masses in von Hippel-Lindau disease: growth rates and clinical outcome over a median follow-up period of 56 months.

Zhang J, Pan JH, Dong BJ, Xue W, Liu DM, Huang YR.

Fam Cancer. 2012 Jun;11(2):209-14. doi: 10.1007/s10689-011-9503-5.

PMID:
22203439
18.

Metastases to hemangioblastomas in von Hippel-Lindau disease.

Jarrell ST, Vortmeyer AO, Linehan WM, Oldfield EH, Lonser RR.

J Neurosurg. 2006 Aug;105(2):256-63.

PMID:
17219831
19.

The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.

Koochekpour S, Jeffers M, Wang PH, Gong C, Taylor GA, Roessler LM, Stearman R, Vasselli JR, Stetler-Stevenson WG, Kaelin WG Jr, Linehan WM, Klausner RD, Gnarra JR, Vande Woude GF.

Mol Cell Biol. 1999 Sep;19(9):5902-12.

20.

Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review.

Kim BJ, Kim JH, Kim HS, Zang DY.

Oncotarget. 2017 Feb 21;8(8):13979-13985. doi: 10.18632/oncotarget.14704. Review.

Supplemental Content

Support Center